Daniel Cho
Division of Hematology and Oncology
Beth Israel Deaconess Medical Center
Boston
Massachusetts; Comprehensive Cancer Centers of Nevada
Nevada
Name/email consistency: high
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cho, D.C., Hutson, T.E., Samlowski, W., Sportelli, P., Somer, B., Richards, P., Sosman, J.A., Puzanov, I., Michaelson, M.D., Flaherty, K.T., Figlin, R.A., Vogelzang, N.J. Cancer (2012)
- The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Cho, D.C., Cohen, M.B., Panka, D.J., Collins, M., Ghebremichael, M., Atkins, M.B., Signoretti, S., Mier, J.W. Clin. Cancer Res. (2010)
- Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. Cho, D.C., Puzanov, I., Regan, M.M., Schwarzberg, T., Seery, V., Lee, M.Y., Liu, V., Bhatt, R., Koon, H., Mier, J.W., Sosman, J.A., Atkins, M.B., McDermott, D.F. J. Immunother. (2009)
- Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., Youmans, A., Polivy, A., Mandato, L., McDermott, D., Stanbridge, E., Atkins, M. Clin. Genitourin. Cancer (2007)